Table 1 Table highlighting polyamine metabolism targeting inhibitors tested in preclinical and/or clinical studies.

PA, polyamine.

Preclinical studies
DFMOODC1Prostate cancer(101, 102)
Pancreatic cancer(103)
Breast cancer(104, 105)
Colon cancer(106)
Neuroblastoma(107, 108)
Live cancer(109)
MGBCPAMD1Prostate cancer(102)
SAM486A (CGP48664)AMD1Bladder cancer, melanoma(113)
ORI 1202*PA transporterBreast cancer(105)
Prostate cancer(101)
BENSpm/DENSpm# [N (1),N (11)bis(ethyl)norspermine]PA analogBreast cancer(114)
PG11047/CGC-11047#PA analogLung cancer(115)
Prostate and lung cancer(116)
Pediatric tumors(117)
SL11144/ CGC-11144PA analogBreast cancer(118)
Clinical trials
InhibitorTargetCancer typeReference
DFMOODC1Prostate cancer(119)
Lung and colon cancer(120)
MGBCPAMD1Prostate cancer(119)
SAM486A (CGP48664)AMD1Solid tumors(18, 19, 121, 122)
Non-Hodgkin’s lymphoma(121, 123)
BENSpm/DENSpm# [N1,N11-bis(ethyl)norspermine]PA analogSolid tumors(124)
Non–small cell lung cancer(125)
Metastatic breast cancer(126)
DEHSPM (N1,N14-diethyl homospermine)PA analogSolid tumors(127)
PG11047/CGC-11047#PA analogSolid, NCT00705653
Solid tumors and, NCT00705874

*In combination with other inhibitors.

#As a single agent and in combination with chemotherapy.